Antidepressant-like effects of auraptenol in mice

Xiaosu Gu1,2,3, Yong Zhou4, Xiaomei Wu5, Fen Wang1,2, Cai-Yi Zhang1,2, Chenchen Du1,2, Lihua Shen3, Xiang Chen3, Jiansheng Shi3, Chunfeng Liu1,2 & Kaifu Ke3

1The Department of Neurology, Second Affiliated Hospital of Soochow University, Suzhou, Jiangsu, 215000 China, 2Institute of Neuroscience, Soochow University, Suzhou, Jiangsu, 215123 China, 3Department of Neurology, Affiliated Hospital of Nantong University, Nantong, Jiangsu, 226001 China, 4The Department of Neurology, The First People’s Hospital of Nantong, Nantong, Jiangsu, 226001 China, 5Department of Neuropharmacology, Institute of Nautical Medicine, Nantong University, Nantong, Jiangsu, 226001 China.

Depression is a major psychiatric disorder affecting nearly 21% of the world population and imposes a substantial health burden on society. Current available antidepressants are not adequate to meet the clinical needs. Here we report that auraptenol, an active component of the traditional Chinese medicine, angelicae dahuricae radix, had antidepressant-like effects in mice models of depression. In mouse forced swimming test and tail suspension test, two validated models of depression, auraptenol dose-dependently decreased the immobility duration within the dose range of 0.05–0.4 mg/kg. In addition, the antidepressant-like effects of auraptenol was significantly averted by a selective serotonin 5-HT1A receptor antagonist WAY100635 (1 mg/kg). These doses that affected the immobile response did not affect locomotor activity. In summary, this study for the first time identified an active component from the herbal medicine angelicae dahuricae radix that possesses robust antidepressant-like efficacy in mice. These data support further exploration for the possibility of developing auraptenol as a novel antidepressant agent in the treatment of major depression disorders.

Depression is a major psychiatric disorder affecting nearly 21% of the world population and imposes a substantial health burden on society. There are three main kinds of classical antidepressants in clinical practice, including tricyclic antidepressants, selective serotonin reuptake inhibitors (SSRIs) and monoamine oxidase inhibitors (MAOIs). Most of these drugs, however, have undesirable side effects and their mechanisms of action have not been satisfactorily resolved. A growing number of herbal medicines are being introduced into psychiatric practice, many of which have comparable efficacy to prescription medications with lower side effects. This makes herbal therapies as desirable alternative treatment for severe depression.

Angelicae dahuricae radix is a perennial plant that grows naturally in broad areas of China. Angelicae dahuricae radix has a strong scent and its leaves are used to make incense. In addition, the roots of angelicae dahuricae radix (also known as Bai Zhi) are used in traditional Chinese medicine to treat harmful external influences on the skin, such as cold, heat, dampness and dryness. Modern pharmacological studies on angelicae dahuricae radix have reported that crude extracts of angelicae radix possess anti-inflammatory, analgesic and antipyretic actions and acute toxicity as a guideline for clinic application. Essential oil of angelicae radix has analgesic effect in rat models of pain, and the antinociceptive effects have been linked to the facilitated release of endogenous opioids such as beta-endorphin. More importantly, angelicae radix has been used clinically to treat depressive symptoms. However, the crude extract and essential oil of angelicae radix include multiple potentially active chemical compounds and the active ingredient(s) of angelicae radix that are responsible for its antidepressant-like activity are currently unknown. Recent phytochemical research has purified and identified several active coumarin components of angelicae radix, and further pharmacological studies are needed to identify the active coumarin component underlying the antidepressant-like actions of angelicae radix.

This study reported the potent antidepressant-like effects of an active coumarin component of angelicae radix, auraptenol (8-(2-hydroxy-3-methylbut-3-en-1-yl)-7-methoxy-2H-chromen-2-one), in mice models of depression. Receptor mechanism underlying the antidepressant-like effects of auraptenol was also studied.
Results

As shown in Figure 1, the potential antidepressant-like effects of auraptenol were evaluated in mouse forced swimming test. Auraptenol showed a dose-dependent reduction of the duration of immobility after acute drug administration, leading to a maximum of 46.3% immobility reduction at a dose of 0.4 mg/kg. The classical antidepressant agent imipramine (10 mg/kg, i.p.) also significantly decreased the immobility time that reached 53.4% reduction of the immobility time. One way ANOVA revealed a significant effect of auraptenol dose ($F (4, 35) = 12.43, P < 0.001$ vs. control group). Post hoc analyses indicated that 0.2 and 0.4 mg/kg auraptenol significantly decreased the immobility time in mice (Fig. 1).

Figure 2 showed the potential antidepressant-like effects of auraptenol in mouse tail suspension test. Auraptenol showed a dose-dependent reduction of the duration of immobility after acute drug administration, leading to a maximum of 44.7% immobility reduction at a dose of 0.4 mg/kg. The classical antidepressant agent imipramine (10 mg/kg, i.p.) also significantly decreased the immobility time that reached 49.1% reduction of the immobility time. One way ANOVA revealed a significant effect of auraptenol dose ($F (4, 35) = 21.46, P < 0.001$ vs. control group). Post hoc analyses indicated that 0.1, 0.2 and 0.4 mg/kg auraptenol significantly decreased the immobility time in mice (Fig. 2).

In order to examine the potential receptor mechanism of auraptenol in both mouse models of depression, the selective 5-HT$_{1A}$ receptor antagonist WAY100635 was studied as a pretreatment with auraptenol in the behavioral assays. In both assays, a dose of 1 mg/kg WAY100635 pretreatment significantly blocked the effects of auraptenol ($F (2, 21) = 9.42, P < 0.05$ in forced swimming test; $F (2, 21) = 11.04, P < 0.01$) (Fig. 3).

The potential effect of auraptenol treatment on the general locomotor activity in naive mice was examined with different doses of auraptenol (Fig. 4). It was found that auraptenol had no significant effect in decreasing the general locomotor activity in mice across the dose range studied. One-way ANOVA found no significant effect on auraptenol dose ($F (4, 35) = 0.48, P > 0.05$). Post hoc analysis revealed that none of the auraptenol doses significantly altered the locomotor activity (Fig. 4).

Discussion

Here we reported that an active component from the plant, angelicae dahuricae radix, produced potent anti-depressant-like effects in two well-validated mouse models of depression, forced swimming test and tail suspension test. Preliminary pharmacological mechanism
The finding that the antidepressant-like effect of auraptenol was of depression, without apparent adverse effects (motor alteration).

receptor binding of auraptenol and future studies that utilize receptors possess robust antidepressant-like effects in both models. The present study demonstrated that auraptenol at systemic doses of 0.2 mg/kg or higher exerted a significant effect to reduce the immobility time after acute administration both in the tail suspension and forced swimming tests in mice. Acute treatment with the classical antidepressant imipramine (10 mg/kg, i.p.) also significantly reduced the immobility time. The antidepressant-like effects of auraptenol were largely comparable to those found with imipramine (10 mg/kg, i.p.). Furthermore, we did not observe any evidence indicating a change in locomotor activity in mice at the doses that significantly improved antidepressant performance. Thus, the antidepressant-like effect of auraptenol is unlikely to be due to an increase in locomotor activity. These results clearly demonstrated for the first time, the antidepressant-like efficacy of auraptenol in the mouse models of depression.

Serotonin 5-HT$_{1A}$ receptors have been shown to involve the pathophysiology of depression and drugs activating 5-HT$_{1A}$ receptors possess robust antidepressant-like effects in various rodent models of depression. For example, 5-HT$_{1A}$ receptor agonists decrease the duration of immobility in a rat forced swimming test and the effectiveness of the ligands are positively correlated with their efficacy for activating 5-HT$_{1A}$ receptors. In this study, the antidepressant-like effects of auraptenol were significantly blocked by a selective 5-HT$_{1A}$ receptor antagonist, WAY106065, in both mouse models of depression. This results strongly suggest the dominant role of 5-HT$_{1A}$ receptors in the observed antidepressant-like effects of auraptenol. This result is significant because auraptenol is a compound that exists in the nature and could provide a broad range of utilities related to 5-HT$_{1A}$ receptor agonism. It should be noted that the fact that effect of auraptenol is blocked by 5-HT$_{1A}$ receptor antagonists does not automatically translate to 5-HT$_{1A}$ receptor agonism. A secondary mechanism is also possible in that auraptenol works on a certain target which in turns functionally activates 5-HT$_{1A}$ receptors. We know of no studies that directly measure the receptor binding of auraptenol and future studies that utilize receptor binding technique will directly address this issue.

In summary, this study for the first time demonstrated that auraptenol has a potent antidepressant-like effect in two mouse models of depression, without apparent adverse effects (motor alteration). The finding that the antidepressant-like effect of auraptenol was primarily mediated by activation of 5-HT$_{1A}$ receptors is consistent with a large body of literature that 5-HT$_{1A}$ receptors are critically involved in the etiology and pathophysiology of depression. Thus, these data may suggest another potential antidepressant agent that works through 5-HT$_{1A}$ receptors and this hypothesis is worth testing in more details in future studies.

---

### Methods

**Animals.** Male C57BL/6 mice weighing 16–22 g (Wetong Lihua, Beijing, China) were used (adapted to the temperature, humidity and lighting (12 h light/dark cycle, lights on at 7:00 AM) controlled vivarium and housed in groups of four for at least one week before behavioral studies began. The animals had free access to dietary food and water except during the test sessions. All animal experimental protocols were approved by the Soochow University Committee on Animal Care and Use. Animals were maintained and experiments were conducted in accordance with the Guide for the Care and Use of Laboratory Animals (8th edition, Institute of Laboratory Animals on Life Sciences, National Research Council, National Academy of Sciences, Washington DC). Animals were used only in one experiment.

**Drugs.** Imipramine hydrochloride and WAY106065 maleate salt were purchased from Sigma-Aldrich (St. Louis, MO, USA) and were dissolved in physiological saline. Auraptenol was purchased from Shanghai Lei Yun Shang Pharmaceutical Co. (>95% purity, Shanghai, China) and was dissolved in saline with one drop of acetic acid. Except otherwise noted, all injections were given intraperitoneally in a volume of 1 ml/100 g of body weight.

**Behavioral procedures.** Forced swimming test. The forced swimming test employed is similar to that described elsewhere with minor modification. Briefly, mice had a swimming-stress session for 15 min (pre-test), 24 h before being individually placed in glass cylinders (height: 25 cm; diameter: 10 cm; containing 10 cm of water at 24 ± 1°C). A 6 min test (test). A camera was mounted facing the forced swimming cylinder and all the test events were recorded. Two experienced observers independently scored the behavior blindly and an average of the two scores were used as a final score. A mouse was judged to be immobile when it ceased struggling and remained floating motionless in the water, making only small movements necessary to keep its head above water. The duration of immobility was recorded during the last 4 min of the 6-min testing period.

**Tail suspension test.** The tail suspension test was based on the method of Stern.[44] Animals were suspended 50 cm above the floor by means of an adhesive tape, placed approximately 1 cm from the tip of the tail. The time mice remained immobile was quantified during a test period of 6 min. Mice were considered immobile only when they hung passively and completely motionless. A camera was mounted facing the tail suspension test arena and all the test events were recorded. Two experienced observers independently scored the behavior blindly and an average of the two scores were used as a final score.

**Locomotor activity.** The locomotor activity of naïve mice treated with vehicle or auraptenol was measured automatically with a Small Animal Locomotion Recording Apparatus (Shandong Academy of Medical Sciences, China), which consisted of six acrylic boxes and in each box there was one pyroelectric infrared sensor 4 cm above the floor. The sensor could detect the movements of the mice through infrared radiation. The apparatus recorded only gross movements of the mice, whereas small movements such as grooming or grooming could not be differentiated and recorded. Immediately after drug or vehicle treatment, the mice were put into the boxes and their general locomotor activity was measured for a period of 2 hours.

**Data analyses.** Results were expressed as the mean ± standard error of the mean (S.E.M.). All data were analyzed statistically using one-way analysis of variance (ANOVA), followed by a post hoc Dunnett’s test. Differences with P < 0.05 were considered statistically significant.

---

1. Nemeroff, C. B. The burden of severe depression: a review of diagnostic challenges and treatment alternatives. *Psychiatr. Res.* 149, 180–200 (2007).
2. Li, J. S. et al. A systematic review and meta-analysis of dietary patterns and depression in community-dwelling adults. *Am. J. Clin. Nutr.* 99, 181–197 (2014).
3. Thachil, A. F., Mohan, R. & Bhugra, D. The evidence base of complementary and alternative therapies in depression. *J. Affect. Disord.* 97, 23–35 (2007).
4. Li, H., Dai, Y., Zhang, H. & Xie, C. Pharmacological studies on the Chinese drug radix Angelicae dahuricae. *Zhongguo Zhong Yao Za Zhi* 16, 560–562 (1991).
5. Nie, H. & Shen, Y. J. [Effect of essential oil of Radix Angelicae Dahuricae on beta-endorphin, ACTH, NO and proopiomelanocortin of pain model rats]. *Zhongguo Zhong Yao Za Zhi* 27, 690–693 (2002).
6. Yuan, C. S. et al. Effects of Corydalis yanhusuo and Angelicae dahuricae on cold pressor-induced pain in human: a controlled trial. *J. Clin. Pharmacol.* 44, 1323–1327 (2004).
7. Xie, Y., Zhao, W., Zhou, T., Fan, G. & Wu, Y. An efficient strategy based on MAE, HPLC-DAD-ESI-MS/MS and 2D-prep-HPLC-DAD for the rapid extraction, identification, purification and quantitative analysis of alkaloids from Radix Angelicae Dahuricae. *Phytochem. Anal.* 21, 473–482 (2010).
8. Porsolt, R. D., Le Pichon, M. & Jalfre, M. Depression: a new animal model sensitive to antidepressant treatments. *Nature* 266, 730–732 (1977).
9. Porsolt, R. D., Anton, G., Blavet, N. & Jaille, M. Behavioural despair in rats: a new model sensitive to antidepressant treatments. *Eur. J. Pharmacol.* 47, 379–391 (1978).
10. Steru, L., Chermat, R., Thierry, B. & Simon, P. The tail suspension test: a new method for screening antidepressants in mice. *Psychopharmacology (Berlin)* 85, 367–370 (1985).
11. Li, J. X., Han, R., Deng, Y. P., Chen, S. Q. & Liang, J. H. Different effects of valproate on methamphetamine- and cocaine-induced behavioral sensitization in mice. Behav. Brain Res. 161, 125–132 (2005).
12. García, R. Stress, metaplasticity, and antidepressants. Curr. Mol. Med. 2, 629–638 (2002).
13. Machado, D. G. et al. Antidepressant-like effect of the extract of Rosmarinus officinalis in mice: involvement of the monoaminergic system. Prog. Neuropsychopharmacol. Biol. Psychiatry 33, 642–650 (2009).
14. Celada, P., Bortolozzi, A. & Artigas, F. Serotonin 5-HT1A receptors as targets for agents to treat psychiatric disorders: rationale and current status of research. CNS Drugs 27, 703–716 (2013).
15. Koek, W. et al. 5-HT1A receptor activation and antidepressant-like effects: F13714 has high efficacy and marked antidepressant potential. Eur. J. Pharmacol. 420, 103–112 (2001).

**Author contributions**

C.L., J.S. and K.K. designed the experiments; X.G., Y.Z., X.W., F.W. and C.Z. conducted the experiments; C.L., C.D. and K.K. wrote the main manuscript text; L.S. and X.C. conducted the statistical analyses and prepared the figures. All authors reviewed and approved the manuscript.

**Additional information**

**Competing financial interests**: The authors declare no competing financial interests.

**How to cite this article**: Gu, X.S. et al. Antidepressant-like effects of auraptenol in mice. Sci. Rep. 4, 4433; DOI:10.1038/srep04433 (2014).

This work is licensed under a Creative Commons Attribution 3.0 Unported license. To view a copy of this license, visit http://creativecommons.org/licenses/by/3.0